Stocky turns companies like BETAPRO 3X SP TSX 60 DLY LV BUL into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. Transcend Therapeutics scores 49/100, reflecting mixed signals: modest leadership alignment (45/100) with no founder-CEO pairing or capped MOS suggests potential misalignment between management and shareholders. Without a formal vulnerability assessment, structural risks remain unclear. Early-stage biotech requires flawless capital stewardship; weak governance signals warrant patience until clinical or operational clarity emerges.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for BETAPRO 3X SP TSX 60 DLY LV BUL:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 49/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates BETAPRO 3X SP TSX 60 DLY LV BUL (TCND.TO) at 49/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Transcend Therapeutics scores 49/100, reflecting mixed signals: modest leadership alignment (45/100) with no founder-CEO pairing or capped MOS suggests potential misalignment between management and shareholders. Without a formal v
TCND.TO's current Stocky Verdict is 49/100, placing it in the "Cautious" band. This composite combines a 50/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for BETAPRO 3X SP TSX 60 DLY LV BUL yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
BETAPRO 3X SP TSX 60 DLY LV BUL scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Vulnerability Profile for BETAPRO 3X SP TSX 60 DLY LV BUL covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on TCND.TO — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for TCND.TO in the app.
